Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL)

참고문헌 (149)

1. Hunger, S. P., "Acute lymphoblastic leukemia in children", N. Engl. J. Med, 373, pp.1541~1552 (2015)
2. Terwilliger, T., "Acute lymphoblastic leukemia : a comprehensive review and 2017 update", Blood Cancer J, 7, pp.e577~e577 (2017)
3. Sas, V., "Transient leukemia of Down syndrome", Crit. Rev. Clin. Lab Sci, 56, pp.247~259 (2019)
4. Pui, C. -H., "Acute lymphoblastic leukemia", N. Engl. J. Med, 350, pp.1535~1548 (2004)
5. Vadillo, E., "T cell acute lympho blastic leukemia(T-ALL) : new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies", Blood Rev, 32, pp.36~51 (2018)
6. Belver, L., "The genetics and mechanisms of T cell acute lym phoblastic leukaemia", Nat. Rev. Cancer, 16, pp.494~507 (2016)
7. Inaba, H., "Pediatric acute lymphoblastic leukemia", Haemato logica, 105, pp.2524~2539 (2020)
8. O’Dwyer, K. M., "Optimal approach to T-cell ALL", Hematology, 2022, pp.197~205 (2022)
9. Al-Mahayri, Z. N., "Long-term effects of pediatric acute lymphoblastic leukemia chemotherapy: can recent findings inform old strate gies?", Front. Oncol, 11, pp.710163~ (2021)
10. Uckun, F. M., "Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts : a Children’s Cancer Group study", J. Clin. Oncol, 15, pp.2214~2221 (1997)
11. Ferrando, A. A., "Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia", Cancer Cell, 1, pp.75~87 (2002)
12. Brady, S. W., "The genomic landscape of pediatric acute lymphoblastic leukemia", Nat. Genet, 54, pp.1376~1389 (2022)
13. Wood, B. L., "Prognostic significance of ETP phenotype and minimal residual disease in T-ALL : a Children’s Oncology Group study", Blood, 142, pp.2069~2078 (2023)
14. Coustan-Smith, E., "Early T-cell precursor leukaemia : a subtype of very high risk acute lymphoblastic leukaemia", Lancet Oncol, 10, pp.147~156 (2009)
15. Jain, N., "Early T-cell precursor acute lymphoblastic leukemia", lymphoma(ETP-ALL, Blood, pp.2016, 127[DOI]
16. Conter, V., "Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols : a retrospective analysis", Lancet Haematol, 3, pp.e80~e86 (2016)
17. Sin, C., "Early T-Cell precursor acute lymphoblastic leukemia : diag nosis, updates in molecular pathogenesis, management, and novel therapies", Front. Oncol, 11, pp.750789~ (2021)
18. Liu, Y., "The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia", Nat. Genet, 49, pp.1211~1218 (2017)
19. Zhang, J., "The genetic basis of early T-cell precursor acute lymphoblastic leukaemia", Nature, 481, pp.157~163 (2012)
20. Treanor, L. M., "Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential", J. Exp. Med, 211, pp.701~713 (2014)
21. Niehues, T., "A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies", Leukemia, 13, pp.614~617 (1999)
22. Noronha, E. P., "The profile of immunophenotype and genotype aberrations in subsets of pediatric T-Cell acute lymphoblastic leukemia", Front. Oncol, 9, pp.316~ (2019)
23. Homminga, I., "Integrated transcript and genome analyses reveal NKX2-1and MEF2C as potential oncogenes in T Cell acute lymphoblastic leukemia", Cancer Cell, 19, pp.484~497 (2011)
24. Fattizzo, B., "The physio pathology of T-Cell acute lymphoblastic leukemia : focus on molecular aspects", Front. Oncol, 10, pp.273~ (2020)
25. Kikuchi, A., "Clinical significance of TAL1 gene alteration in childhood T-cell acute lymphoblastic leukemia and lymphoma", Leukemia, 7, pp.933~938 (1993)
26. Bash, R. O., "Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus : a Pediatric Oncology Group study", Blood, 81, pp.2110~2117 (1993)
27. Girardi, T., "The genetics and molecular biology of T-ALL", Blood, 129, pp.1113~1123 (2017)
28. Raetz, E. A., "T-cell acute lymphoblastic leukemia", Hematology, 2016, pp.580~588 (2016)
29. Lim, S. J. S., "How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults", Blood, 141, pp.3019~3030 (2023)
30. Shimony, S., "Nelarabine : when and how to use in the treatment of T-cell acute lymphoblastic leukemia", Blood Adv, 8, pp.23~36 (2024)
31. Teachey, D. T., "Children’s oncology group Trial AALL1231 : a Phase III clinical trial testing Bortezomib in newly diagnosed T-Cell acute lymphoblastic leukemia and lymphoma", J. Clin. Oncol, 40, pp.2106~2118 (2022)
32. Malone, A., "Nelarabine toxicity in children and adolescents with relapsed", refractory T‐ALL, Br. J. Haematol, pp.2017, 179[DOI]
33. Tzoneva, G., "Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL", Nat. Med, 19, pp.368~371 (2013)
34. Dieck, C. L., "Genetics and mechanisms of NT5C2-driven che motherapy resistance in relapsed ALL", Blood, 133, pp.2263~2268 (2019)
35. Clappier, E., "Clonal selection in xenografted human T cell acute lympho blastic leukemia recapitulates gain of malignancy at relapse", J. Exp. Med, 208, pp.653~661 (2011)
36. Cordo’, V., "T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies", Blood Cancer Discov, 2, pp.19~31 (2021)
37. Deangelo, D. J., "A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia", lymphoma(T-ALL)and other leukemias, 2006, pp.24, 6585~
38. Papayannidis, C., "A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma", Blood Cancer J, 5, pp.e350~ (2015)
39. Ragon, B. K., "Buparlisib, a PI3K inhibitor, demonstrates acceptable toler ability and preliminary activity in a phase I trial of patients with advanced leukemias", Am. J. Hematol, 92, pp.7~11 (2017)
40. Armstrong, F., "NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity", Blood, 113, pp.1730~1740 (2009)
41. Triplett, T. A., "Endogenous dendritic cells from the tumor microenviron ment support T-ALL growth via IGF1R activation", Proc. Natl Acad. Sci. USA, 113, pp.E1016~E1025 (2016)
42. Lyu, A., "Tumor-associated myeloid cells provide critical support for T-ALL", Blood, 136, pp.1837~1850 (2020)
43. Lyu, A., "Integrin signaling is critical for myeloid-mediated support of T-cell acute lymphoblastic leukemia", Nat. Commun, 14, pp.6270~ (2023)
44. Lancaster, J. N., "Chemokine-mediated choreography of thymocyte development and selection", Trends Immunol, 39, pp.86~98 (2018)
45. Ashby, K. M., "A guide to thymic selection of T cells", Nat. Rev. Immunol, 24, pp.103~117 (2024)
46. Koch, U., "Delta-like 4 is the essential, nonredundant ligand for Notch1during thymic T cell lineage commitment", J. Exp. Med, 205, pp.2515~2523 (2008)
47. Shitara, S., "IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCRγδ+ intraepithelial lymphocytes", J. Immunol, 190, pp.6173~6179 (2013)
48. Peschon, J. J., "Early lymphocyte expansion is severely impaired in inter leukin 7 receptor-deficient mice", J. Exp. Med, 180, pp.1955~1960 (1994)
49. Zamisch, M., "Ontogeny and regulation of IL-7-Expressing thymic epithelial cells", J. Immunol, 174, pp.60~67 (2005)
50. Mazzucchelli, R. I., "Visualization and identification of IL-7 producing cells in reporter mice", PLoS ONE, 4, pp.e7637~ (2009)
51. Mazzucchelli, R., "Interleukin-7 receptor expression : intelligent design", Nat. Rev. Immunol, 7, pp.144~154 (2007)
52. Freeden-Jeffry, U., "The Earliest T Lineage–committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression", Immunity, 7, pp.147~154 (1997)
53. Shah, D. K., "An overview of the intrathymic intricacies of T Cell development", J. Immunol, 192, pp.4017~4023 (2014)
54. Trigueros, C., "Pre-TCR signaling regulates IL-7 receptor α expression pro moting thymocyte survival at the transition from the double-negative to dou ble-positive stage", Eur. J. Immunol, 33, pp.1968~1977 (2003)
55. Hong, C., "Intrathymic IL-7: the where, when, and why of IL-7 signaling during T cell development", Semin. Immunol, 24, pp.151~158 (2012)
56. Boudil, A., "IL-7 coordinates proliferation, differentiation and Tcra recom bination during thymocyte β-selection", Nat. Immunol, 16, pp.397~405 (2015)
57. Silva, A., "Overexpression of wild-type IL-7Rα promotes T-cell acute lym phoblastic leukemia", lymphoma, 2021, pp.138, 1040~1052
58. Courtois, L., "IL7-receptor expression is frequent in T-cell acute lympho blastic leukemia and predicts sensitivity to JAK-inhibition", Blood, 142, pp.158~171 (2023)
59. Scupoli, M. T., "Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts : the role of interleukin-7", Haematologica, 88, pp.1229~1237 (2003)
60. Scupoli, M. T., "Interleukin 7 requirement for survival of T-cell acute lym phoblastic leukemia and human thymocytes on bone marrow stroma", Haema tologica, 92, pp.264~266 (2007)
61. Silva, A., "IL-7 contributes to the progression of human T-cell acute lym phoblastic leukemias", Cancer Res, 71, pp.4780~4789 (2011)
62. Li, X., "Notch Signaling in T-Cell Development and T-ALL", ISRN Hematol, 2011, pp.921706~ (2011)
63. Radtke, F., "Deficient T cell fate specification in mice with an induced inactivation of Notch1", Immunity, 10, pp.547~558 (1999)
64. Pui, J. C., "Notch1 expression in early lymphopoiesis influences B versus T lineage determination", Immunity, 11, pp.299~308 (1999)
65. Shi, J., "Nonoverlapping functions for Notch1and Notch3 during murine steady-state thymic lymphopoiesis", Blood, 118, pp.2511~2519 (2011)
66. Struhl, G., "Presenilin-mediated transmembrane cleavage is required for Notch signal transduction in Drosophila", Proc. Natl Acad. Sci. USA, 98, pp.229~234 (2001)
67. Weng, A. P., "c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia", lymphoma, 2006, pp.20, 2096~2109
68. Palomero, T., "NOTCH1 directly regulates c-MYC and activates a feed forward-loop transcriptional network promoting leukemic cell growth", Proc. Natl Acad. Sci. USA, 103, pp.18261~18266 (2006)
69. Sharma, V. M., "Notch1 contributes to mouse T-Cell leukemia by directly inducing the expression of c-myc", Mol. Cell Biol, 26, pp.8022~8031 (2006)
70. Medyouf, H., "High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling", J. Exp. Med, 208, pp.1809~1822 (2011)
71. Ellisen, L. W., "TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms", Cell, 66, pp.649~661 (1991)
72. Weng, A. P., "Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia", Science, 306, pp.269~271 (2004)
73. Thompson, B. J., "The SCFFBW7 ubiquitin ligase complex as a tumor sup pressor in T cell leukemia", J. Exp. Med, 204, pp.1825~1835 (2007)
74. Lobry, C., "Oncogenic and tumor suppressor functions of Notch in cancer : it’s NOTCH what you think", J. Exp. Med, 208, pp.1931~1935 (2011)
75. Ullrich, A., "Insulin-like growth factor I receptor primary structure : com parison with insulin receptor suggests structural determinants that define functional specificity", EMBO J, 5, pp.2503~2512 (1986)
76. Kecha, O., "Involvement of insulin-like growth factors in early T cell devel opment : a study using fetal thymic organ cultures 1", Endocrinology, 141, pp.1209~1217 (2000)
77. Adams, T. E., "Structure and function of the type 1 insulin-like growth factor receptor", Cell Mol. Life Sci, 57, pp.1050~1093 (2000)
78. Sjögren, K., "Liver-derived insulin-like growth factor I(IGF-I)is the principal source of IGF-I in blood but is not required for postnatal body growth in mice", Proc. Natl Acad. Sci. USA, 96, pp.7088~7092 (1999)
79. Laron, Z., "Insulin-like growth factor 1(IGF-1) : a growth hormone", Mol. Pathol, 54, pp.311~316 (2001)
80. Pollak, M. N., "Insulin-like growth factors and neoplasia", Nat. Rev. Cancer, 4, pp.505~518 (2004)
81. Gusscott, S., "Insulin-like growth factor(IGF)signaling in T-cell acute lymphoblastic leukemia", Adv. Biol. Regul, 74, pp.100652~ (2019)
82. Gusscott, S., "IGF1R Derived PI3K", AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias, 2016, pp.11, e0161158~
83. Chen, S. -Y., "Organ-specific microenvironment modifies diverse functional and phenotypic characteristics of leukemia-associated macrophages in mouse T cell acute lymphoblastic leukemia", J. Immunol, 194, pp.2919~2929 (2015)
84. Yang, X., "Hepatic leukemia-associated macrophages exhibit a pro inflammatory phenotype in Notch1-induced acute T cell leukemia", Immuno biology, 223, pp.73~80 (2018)
85. Yang, F., "Monocyte-derived leukemia-associated macrophages facilitate extramedullary distribution of T-cell acute lymphoblastic leukemia cells", Cancer Res, 80, pp.3677~3691 (2020)
86. Reagan, M. R., "Navigating the bone marrow niche : translational insights and cancer-driven dysfunction", Nat. Rev. Rheumatol, 12, pp.154~168 (2016)
87. Passaro, D., "Microenvironmental cues for T‐cell acute lymphoblastic leukemia development", Immunol. Rev, 271, pp.156~172 (2016)
88. Witkowski, M. T., "Mapping and targeting of the leu kemic microenvironment", J. Exp. Med, 217, pp.e20190589~ (2019)
89. Boyerinas, B., "Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy", Blood, 121, pp.4821~4831 (2013)
90. Passaro, D., "CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia", Cancer Cell, 27, pp.769~779 (2015)
91. Pitt, L. A., "CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance", Cancer Cell, 27, pp.755~768 (2015)
92. Morrison, S. J., "The bone marrow niche for haematopoietic stem cells", Nature, 505, pp.327~334 (2014)
93. Greenbaum, A., "CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance", Nature, 495, pp.227~230 (2013)
94. Ding, L., "Haematopoietic stem cells and early lymphoid pro genitors occupy distinct bone marrow niches", Nature, 495, pp.231~235 (2013)
95. Medyouf, "Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia", Nat. Med, 13, pp.736~741 (2007)
96. Gachet, S., "Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia", Leukemia, 27, pp.2289~2300 (2013)
97. Bueno, O. F., "Defective T cell development and function in calcineurin Aβ-deficient mice", Proc. Natl Acad. Sci. USA, 99, pp.9398~9403 (2002)
98. Neilson, J. R., "Calcineurin B1 is essential for positive but not negative selection during thymocyte development", Immunity, 20, pp.255~266 (2004)
99. Bhojwani, D., "Relapsed childhood acute lymphoblastic leukaemia", Lancet Oncol, 14, pp.e205~e217 (2013)
100. Gregorj, C., "ERK1", 2 phosphorylation is an independent predictor of com plete remission in newly diagnosed adult acute lymphoblastic leukemia, 2007, pp.109, 5473~5476
101. Uzan, B., "Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression", EMBO Mol. Med, 6, pp.821~834 (2014)
102. Nakanishi, K., "Unique action of Interleukin-18 on T cells and other immune cells", Front. Immunol, 9, pp.763~ (2018)
103. Duarte, D., "The interplay of leukemia cells and the bone marrow microenvironment", Blood, 131, pp.1507~1511 (2018)
104. Humphries, J. D., "Integrin ligands at a glance", J. Cell Sci, 119, pp.3901~3903 (2006)
105. Gattazzo, F., "Extracellular matrix : a dynamic micro environment for stem cell niche", Biochim. Biophys. Acta, 1840, pp.2506~2519 (2014)
106. Chapman, N. M., "Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement", Immunol. Res, 59, pp.23~34 (2014)
107. Cox, O. T., "IGF-1 receptor and adhesion signaling : an important axis in determining cancer cell phenotype and therapy resistance", Front. Endocrinol, 6, pp.106~ (2015)
108. Cooper, J., "Integrin signaling in cancer : mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance", Cancer Cell, 35, pp.347~367 (2019)
109. Winter, S. S., "Enhanced T-lineage acute lymphoblastic leukaemia cell sur vival on bone marrow stroma requires involvement of LFA-1 and ICAM-1", Br. J. Haematol, 115, pp.862~871 (2001)
110. Berrazouane, S., "Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia", Cell Death Dis, 10, pp.357~ (2019)
111. Hawkins, E. D., "T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments", Nature, 538, pp.518~522 (2016)
112. Lancrin, C., "Major T cell progenitor activity in bone marrow–derived spleen colonies", J. Exp. Med, 195, pp.919~929 (2002)
113. Maillard, I., "Notch-dependent T-lineage commitment occurs at extrathymic sites following bone marrow transplantation", Blood, 107, pp.3511~3519 (2006)
114. Xiong, H., "Spleen plays a major role in DLL4-driven acute T-cell lympho blastic leukemia", Theranostics, 11, pp.1594~1608 (2021)
115. Grande, A. D., "The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL", Blood Adv, 5, pp.1963~1976 (2021)
116. Pelusi, N., "The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm", Sci. Rep, 7, pp.41427~ (2017)
117. Bührer, E. D., "Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance", Leukemia, 36, pp.2634~2646 (2022)
118. Ellyard, J. I., "Contribution of stromal cells to the migration, function and retention of plasma cells in human spleen : potential roles of CXCL12, IL-6 and CD54", Eur. J. Immunol, 35, pp.699~708 (2005)
119. Umemoto, E., "Constitutive plasmacytoid dendritic cell migration to the splenic white pulp is cooperatively regulated by CCR7-and CXCR4-Mediated signaling", J. Immunol, 189, pp.191~199 (2012)
120. Oellerich, T., "β2 integrin–derived signals induce cell survival and pro liferation of AML blasts by activating a Syk", STAT signaling axis, 2013, pp.121, 3889~3899
121. Thastrup, M., "Central nervous system involvement in childhood acute lymphoblastic leukemia : challenges and solutions", Leukemia, 36, pp.2751~2768 (2022)
122. Kopmar, N. E., "How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia", Blood, 141, pp.1379~1388 (2023)
123. Ganzel, C., "CNS involvement in AML at diagnosis is rare and does not affect response or survival : data from 11 ECOG-ACRIN trials", Blood Adv, 5, pp.4560~4568 (2021)
124. Barredo, J. C., "Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation : a pediatric oncology group study", J. Clin. Oncol, 24, pp.3142~3149 (2006)
125. Fielding, A. K., "Outcome of 609 adults after relapse of acute lymphoblastic leukemia(ALL); an MRC UKALL12", ECOG 2993 study, 2007, pp.109, 944~950
126. Jost, T. R., "Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia", J. Leukoc. Biol, 99, pp.1077~1087 (2016)
127. März, M., "Pediatric acute lymphoblastic leukemia—Conquering the CNS across the choroid plexus", Leuk. Res, 71, pp.47~54 (2018)
128. Ribera, J.-M., "T-ALL in CNS-3 status needs improvement", Blood, 141, pp.1779~1780 (2023)
129. Buonamici, S., "CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia", Nature, 459, pp.1000~1004 (2009)
130. Columba-Cabezas, S., "Lymphoid Chemo kines CCL19 and CCL21 are Expressed in the central nervous system during experimental autoimmune encephalomyelitis : implications for the maintenance of chronic neuroinflammation", Brain Pathol, 13, pp.38~51 (2003)
131. Cupovic, J., "Central nervous system stromal cells control Local CD8+ T cell responses during virus-induced neuroinflammation", Immunity, 44, pp.622~633 (2016)
132. O’Connor, T., "Age-related gliosis promotes central nervous system lym phoma through CCL19-mediated tumor cell retention", Cancer Cell, 36, pp.250~267 (2019)
133. Thome, M., "CARMA1, BCL-10 and MALT1 in lymphocyte development and activation", Nat. Rev. Immunol, 4, pp.348~359 (2004)
134. Oruganti, S. R., "CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS", Leukemia, 31, pp.255~258 (2017)
135. Walker, K. L., "CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1", 2 and BCL2 inhibition through CNS infiltration, 2021, pp.62, 1167~1177
136. Cugurra, A., "Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma", Science, 373, pp.eabf7844~ (2021)
137. Masuda, T., "Specification of CNS macrophage subsets occurs postnatally in defined niches", Nature, 604, pp.740~748 (2022)
138. Binnewies, M., "Understanding the tumor immune microenvironment(TIME)for effective therapy", Nat. Med, 24, pp.541~550 (2017)
139. Fahy, L., "Hypoxia favors chemoresistance in T-ALL through an HIF1αmediated mTORC1 inhibition loop", Blood Adv, 5, pp.513~526 (2021)
140. Wang, J., "Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells", J. Hematol. Oncol, 11, pp.11~ (2018)
141. Hanna, G. J., "A Phase I study of the pan-notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors", Cancer Res. Commun, 3, pp.1853~1861 (2023)
142. Uy, G. L., "CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia", Lymphoblastic Lymphoma, 2019, pp.134, 2630~
143. Lacy, M. Q., "Phase I, pharmacokinetic and pharmacodynamic study of the anti–insulinlike growth factor Type 1 receptor monoclonal antibody CP-751, 871in patients with multiple myeloma", J. Clin. Oncol, 26, pp.3196~3203 (2008)
144. Hansson, M., "A Phase I dose-escalation study of antibody BI-505 in relapsed", refractory multiple myeloma, 2015, pp.21, 2730~2736
145. Poirier, N., "First-in-human study in healthy subjects with the noncytotoxic monoclonal antibody OSE-127, a strict antagonist of IL-7Rα", J. Immunol, 210, pp.753~763 (2023)
146. Akkapeddi, P., "A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia", Leukemia, 33, pp.2155~2168 (2019)
147. Hixon, J. A., "New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models", Leukemia, 34, pp.35~49 (2020)
148. Lenk, L., "The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis", Blood, 143, pp.2735~2748 (2024)
149. Maude, S. L., "Targeting JAK1", 2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia, 2012, pp.120, 3510~3518

관련 논문AI추천